

# BioNTech starts vaccine production at new German site

10 February 2021



BioNTech's site in Marburg is expected to be one of the largest mRNA production facilities in Europe, with an annual production capacity of up to 750 million vaccine doses

German Covid-19 vaccine maker BioNTech said Wednesday it has started production at its new facility in Marburg, expected to significantly boost the EU's vaccine supply.

"We have started the first step of vaccine production in our [production facility](#) in Marburg," the company said in a statement.

The factory, whose launch was fast-tracked by German authorities, will produce mRNA, the [active ingredient](#) in BioNTech's vaccine developed with US pharmaceutical giant Pfizer.

It will then be purified and concentrated before being transported to a "production partner" to be finished.

The European Medicines Agency (EMA) will carry out quality checks in February or March.

"The first vaccines produced at the Marburg site

are expected to be delivered at the beginning of April," BioNTech said.

The main European factory for producing the vaccine is Pfizer's plant in Puurs, Belgium.

Once fully operational, the new Marburg site in Hesse state will be one of the largest mRNA production facilities in Europe, with an annual production capacity of up to 750 million [vaccine doses](#).

BioNTech plans to produce up to 250 million doses there in the first half of 2021.

"We continue to work with Pfizer on a series of measures to meet [global demand](#)," said the company, confirming its goal of delivering two billion doses in 2021.

BioNTech bought the Marburg plant from Swiss pharma giant Novartis last year to ramp up vaccine production, and retained the 300 employees already working there.

BioNTech had announced in mid-January that it would have to delay shipments of the jabs to the EU due to necessary modifications at the Puurs factory, sparking ire across the bloc.

But the company said in early February it would meet its contractual commitments for the first quarter and pledged to send up to 75 million extra doses to the bloc in the spring.

The EU has ordered a total of 600 million doses of BioNTech and Pfizer's so-called Comirnaty vaccine.

© 2021 AFP

APA citation: BioNTech starts vaccine production at new German site (2021, February 10) retrieved 25 August 2022 from

<https://medicalxpress.com/news/2021-02-biontech-vaccine-production-german-site.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*